ArticleSeminars in arthritis and rheumatism2020
Long, relapsing, and atypical symptomatic course of COVID-19 in a B-cell-depleted patient after rituximab.
Article in Seminars in arthritis and rheumatism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- COVID-19 course in granulomatosis with polyangiitis: single center experience with review of the literature.Turkish journal of medical sciences · 2022Pooled it
- [Recommendations of the German Society for Rheumatology for management of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic - Update July 2020].Zeitschrift fur Rheumatologie · 2020Guideline
- Clinical Characteristics, Prognostic Factors, and Outcomes of COVID-19 in Autoimmune Rheumatic Disease Patients: A Retrospective Case-Control Study from Astana, Kazakhstan.Medicina (Kaunas, Lithuania) · 2024Article
- COVID-19 Vaccination and Disease Course in People with Multiple Sclerosis in Greece.Journal of clinical medicine · 2023Article
- Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Article
- CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases.Frontiers in medicine · 2023Article
- COVID-19 in patients with B cell immune deficiency.Journal of immunological methods · 2022Article
- Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study.ACR open rheumatology · 2022Article
- Progression of COVID-19 in a Patient on Anti-CD20 Antibody Treatment: Case Report and Literature Review.Case reports in infectious diseases · 2022Article
- A Biphasic COVID-19 Clinical Course in Anti-CD20 Treated Patients: Case Series and Review of the Literature.European journal of case reports in internal medicine · 2022Article
- COVID-19 outcomes in persons with multiple sclerosis treated with rituximab.Multiple sclerosis and related disorders · 2022Article
- Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination.Zeitschrift fur Rheumatologie · 2021Review
- Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed.Rheumatology international · 2021Review
- Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β.Journal of clinical immunology · 2021Article
- COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study.medRxiv : the preprint server for health sciences · 2021Article
- The Care of the Leukemic Patients in Times of SARS-CoV-2.Current oncology reports · 2021Review
- [Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination].Zeitschrift fur Rheumatologie · 2021Review
- Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections).Current rheumatology reports · 2021Review
- COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.The Lancet. Rheumatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.